{"id":62196,"date":"2025-11-13T07:03:21","date_gmt":"2025-11-13T06:03:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/"},"modified":"2025-11-13T07:03:21","modified_gmt":"2025-11-13T06:03:21","slug":"virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/","title":{"rendered":"Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines"},"content":{"rendered":"<div>\n<p>SCHLIEREN, Switzerland&#8211;(BUSINESS WIRE)&#8211;<i>Virometix AG<\/i>, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced the completion of a $15 million financing round from existing shareholders. The funds will support continued clinical and development activities for <i>V-212<\/i>, Virometix\u2019s lead serotype-independent pneumococcal vaccine candidate, currently in Phase I clinical evaluation.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20251112846577\/en\/2592092\/5\/Virometix_logo_color_positive.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251112846577\/en\/2592092\/22\/Virometix_logo_color_positive.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251112846577\/en\/2592092\/5\/Virometix_logo_color_positive.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251112846577\/en\/2592092\/21\/Virometix_logo_color_positive.jpg\"><\/a><\/p>\n<p>\nProceeds from the financing will be used to:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nAdvance the ongoing Phase I clinical trial of V-212, with topline results expected in Q1 2026.<\/li>\n<li>\nPrepare for a planned Phase Ib combination trial evaluating V-212 with an approved pneumococcal conjugate vaccine (PCV).<\/li>\n<li>\nComplete OPK assay validation to support immunogenicity and functional data read-outs.<\/li>\n<li>\nImplement platform enhancements to the company\u2019s proprietary <i>Synthetic Virus-Like Particle (SVLP)<\/i> technology.<\/li>\n<li>\nProgress next-generation serotype-independent pneumococcal vaccine programs toward preclinical development.<\/li>\n<\/ul>\n<p>\n\u201cThis financing demonstrates the continued confidence and commitment of our investors to Virometix\u2019s mission and platform,\u201d said <i>Anna Sumeray<\/i>, Chief Executive Officer of Virometix. \u201cOur fully synthetic SVLP technology enables the design of broad-spectrum, self-adjuvanted vaccines with highly scalable manufacturing. With V-212 in clinical development, we are well positioned to deliver a truly next-generation approach to pneumococcal prevention.\u201d<\/p>\n<p>\n<b>About V-212<\/b><\/p>\n<p>\n<i>V-212<\/i> is a fully synthetic, serotype-independent, peptide-based vaccine designed to prevent <i>Streptococcus pneumoniae<\/i>infections. The vaccine incorporates multiple conserved antigenic epitopes from key pneumococcal surface proteins conjugated to Virometix\u2019s proprietary SVLP nanoparticles, which include built-in adjuvant elements such as T-helper epitopes and Toll-like receptor (TLR) ligands. This unique design eliminates dependence on biological carrier proteins and allows for a streamlined, fully synthetic manufacturing process.<\/p>\n<p>\nPreclinical studies demonstrated robust and durable immunogenicity in mouse and rabbit models, protection against lethal sepsis, and cross-reactivity with multiple pneumococcal serotypes, including non-PCV-13 types\u2014underscoring V-212\u2019s potential for broad protection.<\/p>\n<p>\nThe ongoing Phase I clinical trial (NCT06975319) is a randomized, double-blind, placebo-controlled, first-in-human study being conducted at the Centre for Vaccinology (CEVAC), Ghent University Hospital. Sixty healthy volunteers aged 18\u201345 have been enrolled, and topline safety and immunogenicity data are anticipated in the first quarter of 2026.<\/p>\n<p>\n<b>About Virometix<\/b><\/p>\n<p>\n<i>Virometix AG<\/i> is a privately held biotechnology company developing a new generation of fully synthetic vaccines to elicit targeted and protective immune responses against infectious diseases and cancer. The company\u2019s proprietary <i>Synthetic Virus-Like Particle (SVLP)<\/i> platform combines rational molecular design and chemical synthesis to rapidly generate optimized vaccine candidates with superior safety, efficacy, manufacturability, and stability profiles.<\/p>\n<p>\nLearn more at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.virometix.com%2F&amp;esheet=54356334&amp;newsitemid=20251112846577&amp;lan=en-US&amp;anchor=www.virometix.com&amp;index=1&amp;md5=2faae8c7c3edd23d7ac7d2dd799edd21\" rel=\"nofollow\" shape=\"rect\">www.virometix.com<\/a><\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media Contact<\/b><br \/>David Rosen<br \/>\n<br \/>Argot Partners<br \/>\n<br \/>Phone: +1 646.461.6387<br \/>\n<br \/>Email: <a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;:&#100;&#x61;&#x76;i&#100;&#x2e;r&#111;&#x73;&#x65;n&#64;&#x61;r&#103;&#x6f;&#x74;&#112;&#97;&#x72;t&#110;&#x65;&#x72;&#115;&#x2e;&#x63;o&#109;\" rel=\"nofollow\" shape=\"rect\">d&#97;&#118;&#x69;&#x64;&#x2e;ro&#115;&#101;&#x6e;&#x40;&#x61;r&#103;&#111;&#116;&#x70;&#x61;&#x72;t&#110;&#101;&#x72;&#x73;&#x2e;co&#109;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SCHLIEREN, Switzerland&#8211;(BUSINESS WIRE)&#8211;Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced the completion of a $15 million financing round from existing shareholders. The funds will support continued clinical and development activities for V-212, Virometix\u2019s lead serotype-independent pneumococcal vaccine candidate, currently in Phase I clinical evaluation. Proceeds from the financing will be used &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62196","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SCHLIEREN, Switzerland&#8211;(BUSINESS WIRE)&#8211;Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced the completion of a $15 million financing round from existing shareholders. The funds will support continued clinical and development activities for V-212, Virometix\u2019s lead serotype-independent pneumococcal vaccine candidate, currently in Phase I clinical evaluation. Proceeds from the financing will be used ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-13T06:03:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251112846577\/en\/2592092\/22\/Virometix_logo_color_positive.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines\",\"datePublished\":\"2025-11-13T06:03:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\\\/\"},\"wordCount\":421,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251112846577\\\/en\\\/2592092\\\/22\\\/Virometix_logo_color_positive.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\\\/\",\"name\":\"Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251112846577\\\/en\\\/2592092\\\/22\\\/Virometix_logo_color_positive.jpg\",\"datePublished\":\"2025-11-13T06:03:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251112846577\\\/en\\\/2592092\\\/22\\\/Virometix_logo_color_positive.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251112846577\\\/en\\\/2592092\\\/22\\\/Virometix_logo_color_positive.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/","og_locale":"en_US","og_type":"article","og_title":"Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines - Pharma Trend","og_description":"SCHLIEREN, Switzerland&#8211;(BUSINESS WIRE)&#8211;Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced the completion of a $15 million financing round from existing shareholders. The funds will support continued clinical and development activities for V-212, Virometix\u2019s lead serotype-independent pneumococcal vaccine candidate, currently in Phase I clinical evaluation. Proceeds from the financing will be used ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/","og_site_name":"Pharma Trend","article_published_time":"2025-11-13T06:03:21+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251112846577\/en\/2592092\/22\/Virometix_logo_color_positive.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines","datePublished":"2025-11-13T06:03:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/"},"wordCount":421,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251112846577\/en\/2592092\/22\/Virometix_logo_color_positive.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/","url":"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/","name":"Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251112846577\/en\/2592092\/22\/Virometix_logo_color_positive.jpg","datePublished":"2025-11-13T06:03:21+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251112846577\/en\/2592092\/22\/Virometix_logo_color_positive.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251112846577\/en\/2592092\/22\/Virometix_logo_color_positive.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/virometix-ag-announces-completion-of-15-million-financing-round-to-advance-development-of-v-212-and-next-generation-synthetic-vaccines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62196"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62196\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}